SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
UPM-Kymmene Oyj (UPMMY) trades at a trailing P/E of 34.4, forward P/E of 17.1. Trailing earnings yield is 2.91%, forward earnings yield 5.85%. PEG 3.12.
Criteria proven by this page:
- VALUE (40/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 17.1 (down from trailing 34.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 3.12 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 2.91% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 5.85% as earnings recover.
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
40/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — UPMMY
Valuation Multiples
P/E (TTM)34.4
Forward P/E17.1
PEG Ratio3.12
Forward PEG0.17
P/B Ratio0.00
P/S Ratio1.71
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.91
Forward EPS (Est.)$1.83
Book Value / Share$0.00
Revenue / Share$18.27
FCF / Share$0.00
Yields & Fair Value
Earnings Yield2.91%
Forward Earnings Yield5.85%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.65 |
$9.81B |
$879M |
9% |
| 2017 |
$1.82 |
$10.01B |
$973M |
9.7% |
| 2018 |
$2.80 |
$10.48B |
$1.5B |
14.3% |
| 2019 |
$1.99 |
$10.24B |
$1.06B |
10.4% |
| 2020 |
$1.05 |
$8.58B |
$560M |
6.5% |
| 2021 |
$2.41 |
$9.81B |
$1.29B |
13.1% |
| 2022 |
$2.86 |
$11.72B |
$1.53B |
13% |
| 2023 |
$0.73 |
$10.46B |
$388M |
3.7% |
| 2024 |
$0.82 |
$10.34B |
$436M |
4.2% |
| 2025 |
$0.91 |
$9.66B |
$480M |
5% |
